Citations

Showing 10 of 108083 citations.

Focal tonic absence seizure mischaracterized as periodic paralysis: A cautionary tale
Nordli, Douglas R. , Middlebrooks, Erik H. , Feyissa, Anteneh M. , Middlebrooks, Erik, Feyissa, A M , Middlebrooks, Erik H , Nordli Iii, Douglas R

Mayo Clinic

Annals of the Child Neurology Society | January 28, 2023 | Volume: 1 | Issue: 1 | Pages: 82-84

10.1002/cns3.20013 | PMID 42563953 Get It

Extracranial Internal Carotid and Vertebral Dissecting Pseudoaneurysms: Clinical Features and Long‐Term Outcomes
Seven, Nathan A. , Keser, Zafer , Keser, Zafer , Casanegra, Ana I. , Lanzino, Giuseppe

Mayo Clinic

Stroke: Vascular and Interventional Neurology | January 28, 2023 | Volume: 3 | Issue: 3 | Pages: No page available

10.1161/svin.122.000703 | PMID 41584974 Get It

Background The formation of dissecting pseudoaneurysms (dPSAs) is a common sequela of cervical artery dissection, which has been suggested to increase thrombotic risk in previous studies. This study reported clinical features and long‐term outcomes of cervical internal carotid (cICA) and vertebral artery (cVA) dPSAs. Methods We performed a retrospective chart review over a 10‐year period (January 2012–December 2021). Baseline demographics and clinical characteristics, medical and endovascular treatments, and long‐term outcomes were reported for cICA and cVA dPSA groups separately. Nonparametric tests were used to compare group differences. Results In our cohort, 120 (12%) of 999 cervical artery dissection patients had dPSA, with 85% occurring in the cICA and 15% in the cVA. Most dPSAs occurred spontaneously or in association with minor trauma. Compared with cICA dPSA, patients with cVA dPSA were younger (median age [range]=34.5 [24–70] versus 52 [30–77]; P <0.01), had a smaller dPSA size (median size [range]=4.5 mm [2–17] versus 8 mm [1.2–32]; P <0.01), and were more likely to reduce in size at follow‐up (median size change [range]=−2.8 mm [−17;0] versus 0 [−24;10.8]). Antithrombotic therapy was predominately aspirin monotherapy. No patients with cVA dPSA experienced recurrent strokes and only 3% of patients with cICA dPSA developed new/recurrent stroke in the territory of dPSA while on an antithrombotic regimen requiring endovascular intervention, and none of the dPSAs ruptured. A total of 98% of the patients had an excellent outcome (modified Rankin scale 0–2 at final follow‐up). Conclusion Most cICA and cVA dPSAs have a benign prognosis with medical therapy alone. Further prospective randomized clinical trials are needed to provide high quality evidence on the necessity of additional endovascular therapy at diagnosis in addition to medical therapy alone.
GMWI-webtool: a user-friendly browser application for assessing health through metagenomic gut microbiome profiling
Chang, Daniel , Gupta, Vinod K. , Hur, Benjamin, Cunningham, Kevin Y. , Sung, Jaeyun , Sung, Jaeyun

Mayo Clinic

Bioinformatics | January 28, 2023 | Volume: 39 | Issue: 2 | Pages: No page available

10.1093/bioinformatics/btad061 | PMID 36707995 Get It

Abstract Summary We recently introduced the Gut Microbiome Wellness Index (GMWI), a stool metagenome-based indicator for assessing health by determining the likelihood of disease given the state of one’s gut microbiome. The calculation of our wellness index depends on the relative abundances of health-prevalent and health-scarce species. Encouragingly, GMWI has already been utilized in various studies focusing on differences in the gut microbiome between cases and controls. Herein, we introduce the GMWI-webtool, a user-friendly browser application that computes GMWI, health-prevalent/-scarce species’ relative abundances, and α-diversities from stool shotgun metagenome taxonomic profiles. Users of our interactive online tool can visualize their results and compare them side-by-side with those from our pooled reference dataset of metagenomes, as well as export data in.csv format and high-resolution figures. Availability and implementation GMWI-webtool is freely available here: https://gmwi-webtool.github.io/. Supplementary information Supplementary data are available at Bioinformatics online.
Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review
Mir, Nabiel , Burke, Olivia , Yates, Samuel J. , Rajasekaran, Tanujaa , Chan, Johan , Kanesvaran, Ravindran , Kanesvaran, Ravindran , Szmulewitz, Russell Z

Mayo Clinic

Therapeutic Advances in Medical Oncology | January 28, 2023 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/17588359221149887 | PMID 36743522 Get It

Prostate cancer is a disease of older adults that has undergone a significant therapeutic paradigm shift in the last decade with the emergence of novel androgen receptor pathway inhibitors (ARPis). One of the more commonly used ARPis is enzalutamide. This drug, along with darolutamide and apalutamide, initially received approvals in the metastatic castrate-resistant prostate cancer setting but is now utilized frequently in the metastatic castrate-sensitive and non-metastatic castration-resistant settings. Landmark phase III data illustrating ARPi efficacy in older adults are limited to those with excellent performance status. However, its role in unfit older prostate cancer patients remains to be explored in the context of a narrative review. This first-of-its-kind drug review aims to shed light on the most up-to-date evidence behind the unique toxicity profile of ARPis in the context of geriatric vulnerabilities such as cognitive and functional impairment, along with potential solutions and supporting evidence that exists to circumvent these issues in the vulnerable older adult.
Molecular Characteristics of Early-Onset Colorectal Cancer According to Detailed Anatomical Locations: Comparison With Later-Onset Cases
Harrison, Tabitha A. , Cao, Yin , Akimoto, Naohiko , Berndt, Sonja I. , Brenner, Hermann , Chang‐Claude, Jenny , Fujiyoshi, Kenji , Gallinger, Steven , Hoffmeister, Michael , Nishihara, Reiko , Pai, Rish K. , Slattery, Martha L. , Alwers, Elizabeth , Thibodeau, Stephen N. , Guelpen, Bethany Van , Woods, Michael O. , Zaidi, Syed Hassan Ejaz , Giannakis, Marios , Song, Mingyang , Phipps, Amanda I. , Peters, Ulrike , Ogino, Shuji , Hoffmeister, Michael , Cao, Yin , Harrison, Tabitha A , Van Guelpen, Bethany , Brenner, Hermann , Song, Mingyang , Ugai, Tomotaka , Haruki, Koichiro , Qu, Conghui , Chan, Andrew T. , Campbell, Peter T. , Buchanan, Daniel D. , Gunter, Marc J. , Hidaka, Akihisa , Hsu, Li , Jenkins, Mark A. , Milne, Roger L. , Moreno, Vı́ctor , Newcomb, Polly A. , Sakoda, Lori C. , Sun, Wei , Amitay, Efrat L. , Toland, Amanda Ewart , Potter, John D. , Nowak, Jonathan A.

Mayo Clinic

American Journal of Gastroenterology | January 28, 2023 | Volume: 118 | Issue: 4 | Pages: 712-726

10.14309/ajg.0000000000002171 | PMID 36707929 Get It

INTRODUCTION: Early-onset colorectal cancer diagnosed before the age of 50 years has been increasing. Likely reflecting the pathogenic role of the intestinal microbiome, which gradually changes across the entire colorectal length, the prevalence of certain tumor molecular characteristics gradually changes along colorectal subsites. Understanding how colorectal tumor molecular features differ by age and tumor location is important in personalized patient management. METHODS: Using 14,004 cases with colorectal cancer including 3,089 early-onset cases, we examined microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and KRAS and BRAF mutations in carcinomas of the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum and compared early-onset cases with later-onset cases. RESULTS: The proportions of MSI-high, CIMP-high, and BRAF -mutated early-onset tumors were lowest in the rectum (8.8%, 3.4%, and 3.5%, respectively) and highest in the ascending colon (46% MSI-high; 15% CIMP-high) or transverse colon (8.6% BRAF -mutated) (all P trend <0.001 across the rectum to ascending colon). Compared with later-onset tumors, early-onset tumors showed a higher prevalence of MSI-high status and a lower prevalence of CIMP-high status and BRAF mutations in most subsites. KRAS mutation prevalence was higher in the cecum compared with that in the other subsites in both early-onset and later-onset tumors ( P < 0.001). Notably, later-onset MSI-high tumors showed a continuous decrease in KRAS mutation prevalence from the rectum (36%) to ascending colon (9%; P trend <0.001), followed by an increase in the cecum (14%), while early-onset MSI-high cancers showed no such trend. DISCUSSION: Our findings support biogeographical and pathogenic heterogeneity of colorectal carcinomas in different colorectal subsites and age groups.
Subjective and objective burden on providers from a multicenter app-based study of patients with cirrhosis and caregivers
Shaw, Jawaid , Acharya, Chathur , Albhaisi, Somaya , Fagan, Andrew , McGeorge, Sara , White, Melanie B. , Lachar, Jatinder, Olofson, Amy , Bergstrom, Lori , Kamath, Patrick S. , Bajaj, Jasmohan S. , Olson, Jessica, Kamath, Patrick S , Bajaj, Jasmohan S , Albhaisi, Somaya , Shaw, Jawaid , White, Melanie B. , Olson, Jessica

Mayo Clinic

Hepatology Communications | January 27, 2023 | Volume: 7 | Issue: 2 | Pages: e0030-e0030

10.1097/hc9.0000000000000030 | PMID 36706194 Get It

Background: App-based technologies could enhance patient and caregiver communication and provide alerts that potentially reducing readmissions. However, the burden of App alerts needs to be optimized to reduce provider burnout. Aim: The purpose of this study was to determine subjective and objective burden of using the Patient Buddy App, a health information technology (HIT) on providers in a randomized multicenter trial, who completed a semi-quantitative Likert scale survey regarding training procedures, data and privacy concerns, follow-up details, and technical support. This randomized multicenter trial recruits cirrhosis inpatients and their caregivers, and randomizes them into standard-of-care, HIT (communication only via App) and HIT+visits (App+phone calls/visits) for 30 days after discharge. The alerts are monitored by providers through a central iPad. The reason(s) and number of alerts were recorded as the objective burden. A total of 1442 messages were sent as alerts from the 103 dyads (patient + caregiver) (n=206) randomized to HIT arms. The most common messages related to Hepatic Encephalopathy (HE) (high or low bowel movement=50% or orientation tests=37%). Twelve providers completed the surveys reflecting the following themes—92% and 100%, felt adequately trained and confident about educating the patients and caregivers before roll out of App and had no concerns related to data and privacy; 70%, felt that appropriate time was spent on pursuing reason for data not being logged; 60% each, had issues with availability of adequate technical support and connectivity. Conclusion: The Patient Buddy App randomized multicenter trial till date shows an overall favorable rating regarding training procedures/education, privacy concerns, and ease of message follow-up, from providers. However, it is important to gauge and address subjective and objective burdens of monitoring human resources in current and future HIT studies to avoid burnout and to ensure successful study completion.
Assessment of the DASH-TOP Shared decision-making intervention using the decisional conflict scale: A mixed- method study
Humphries, Brittany , Gravholt, Derek, Bates, Shannon M. , Xie, Feng , Gravholt, Derek L. , León‐García, Montserrat , Roca, Pablo , Eckman, Mark H. , Suárez, Nataly R. Espinoza , Alonso‐Coello, Pablo , Perestelo‐Pérez, Lilisbeth

Mayo Clinic

No container title available | January 27, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2488592/v1 Get It

Abstract Background Venous thromboembolism (VTE) in pregnancy is a major cause of maternal morbidity and death. The use of low-molecular-weight heparin (LMWH), despite being the standard of care to prevent VTE, comes with some challenges. Shared decision-making (SDM) interventions are recommended to support patients and clinicians in making preference-sensitive decisions. The quality of the SDM process has been widely assessed with the decisional conflict scale (DCS). Our aim is to report participants’ perspectives of each of the components of an SDM intervention (DASH-TOP) in relation to the different subscales of the DCS. Methods Design: A convergent, parallel, mixed-methods design. Participants: The sample consisted of 22 health care professionals, students of an Applied Clinical Research in Health Sciences (ICACS) master program. Intervention: We randomly divided the participants in three groups: Group 1 received one component (evidence -based information), Group 2 received two components (first component and value elicitation exercises), and Group 3 received all three components (the first two and a decision analysis recommendation) of the SDM intervention. Analysis: For the quantitative strand, we used a non-parametric test to analyze the differences in the DCS subscales between the three groups. For the qualitative strand, we conducted a content analysis using the decisional conflict domains to deductively categorize the responses. Results Groups that received more intervention components experienced less conflict and better decision-making quality, although the differences between groups were not statistically significant. The decision analysis recommendation improved the efficacy with the decision-making process, however there are some challenges when implementing it in clinical practice. The uncertainty subscale showed a high decisional conflict for all three groups; contributing factors included low certainty of the evidence-based information provided and a perceived small effect of the drug to reduce the risk of a VTE event. Conclusions The DASH-TOP intervention reduced decisional conflict in the decision -making process, with decision analysis being the most effective component to improve the quality of the decision. There is a need for more implementation research to improve the delivery of SDM interventions in the clinical encounter.
Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment?
Hogan, Marie C. , Masyuk, Tatyana V. , Hogan, Marie C

Mayo Clinic

Clinical Journal of the American Society of Nephrology | January 27, 2023 | Volume: 18 | Issue: 2 | Pages: 154-156

10.2215/cjn.0000000000000055 | PMID 36754002 Get It

A Clinician's Guide to Targeted Precision Imaging in Patients With Prostate Cancer (RADAR VI)
Crawford, E. David , Albala, David , Harris, Richard G., Slovin, Susan F. , Finkelstein, Steven E., Garnick, Marc B. , Gomella, Leonard G. , Higano, Celestia S. , Koo, Sonya J., Petrylak, Daniel P. , Sellinger, Scott B., McKay, Rana R. , Crosby, Mike, Koo, Phillip J. , Bryce, Alan H. , Carroll, Peter R , Yu, Evan Y , Cooperberg, Matthew R

Mayo Clinic

JU Open Plus | January 27, 2023 | Volume: 1 | Issue: 1 | Pages: No page available

10.1097/ju9.0000000000000003 Get It

Purpose: The advent of new imaging agents offers enhanced sensitivity and specificity in the detection and staging of prostate cancer. A growing array of treatment options and ongoing advancements in imaging technologies allow earlier and more extensive detection of metastatic disease and shifting the boundaries between disease states previously defined by conventional imaging. This review seeks to synthesize existing data and expert opinion to better guide patient management in the new era of targeted precision imaging (TPI). Materials and Methods: The Radiographic Assessments for Detection of Advanced Recurrence VI Group gathered to develop pathways/recommendations regarding how TPI could best be deployed, given approvals of key radiotracers including 18F-fluciclovine, 68Ga-PSMA, and 18F-DCFPyL positron emission tomography/CT. Results: Radiographic Assessments for Detection of Advanced Recurrence VI Group members developed consensus pathways/suggestions based on the best available evidence for use of TPI in prostate cancer. Conclusions: Patients with prostate cancer have the potential to benefit from judicious use of TPI. However, additional research is needed to ensure that TPI is used appropriately and provides actionable findings that inform treatment decisions for these patients.
Sex differences in brain atrophy in dementia with Lewy bodies
Oltra, Javier , Schwarz, Christopher G. , Nedelská, Zuzana , Przybelski, Scott A. , Inguanzo, Anna , Diaz‐Galvan, Patricia , Lowe, Val J. , Oppedal, Ketil , Blanc‬, ‪Frederic, Kramberger, Milica G. , Taylor, John‐Paul , Snædal, Jón , Walker, Zuzana , Westman, Eric , Habich, Annegret , Schwarz, Christopher G , Nedelska, Zuzana , Inguanzo, Anna , Diaz-Galvan, Patricia , Oppedal, Ketil , Lemstra, Afina W , Hort, Jakub , Padovani, Alessandro , Rektorova, Irena , Bonanni, Laura , Massa, Federico , Taylor, John Paul , Snædal, Jon , Walker, Zuzana , Antonini, Angelo , Segura, Barbara , Junque, Carme , Westman, Eric , Boeve, Brad , Aarsland, Dag , Kantarci, Kejal , Ferreira, Daniel , Habich, Annegret , Lemstra, Afina W. , Hort, Jakub , Padovani, Alessandro , Rektorová, Irena , Massa, Federico , Antonini, Angelo , Segura, Bàrbara , Junqué, Carme , Boeve, Bradley F. , Aarsland, Dag , Kantarci, Kejal , Ferreira, Daniel

Mayo Clinic

No container title available | January 27, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2516427/v1 | PMID 36747755 Get It

Abstract Background and objectives. Sex is an important contributing factor to neuroimaging phenotypes in brain disorders. However, little is known about the contribution of sex differences to the neurodegeneration in dementia with Lewy bodies (DLB). We investigated sex differences in probable DLB patients by using both visual rating scales of lobar atrophy and automated estimations of regional atrophy. Methods. We included 442 probable DLB patients from the European-DLB consortium and the Mayo Clinic who have magnetic resonance imaging (MRI) data available. We assessed sex differences and the sex-by-age interaction in two largely independent samples through visual rating scales of lobar atrophy (n = 333; mean age 73 ± 8 years, 62% males) and automated regional estimations of gray matter (GM) volume and mean cortical thickness (CTh) (n = 165; mean age 69 ± 9 years, 72% males). We used binary logistic regression and ANOVA for statistical analysis. Results. We found a statistically significantly higher likelihood of frontal atrophy measured by the global cortical atrophy-frontal subscale (GCA-F) in males (40% of males had an abnormal GCA-F score versus 29% of females, P-value = 0.006). Using automated estimations, we found smaller GM volumes in 6 cortical regions in males compared with females, as well as smaller GM volume in the entorhinal cortex and thinner olfactory cortices in females, compared with males. The sex-by-age interaction showed statistically significant results in 6 cortical volumes and 7 mean CTh estimations (P-value ≤ 0.05), accentuated in the right middle frontal gyrus (FDR-adjusted P-value = 0.047). These cross-sectional interactions indicated that while females have statistically significantly less atrophy than males at younger ages, differences become non-significant at older ages, with females showing the same level of atrophy than males around the age of 75. Conclusions. This study demonstrates sex differences on brain atrophy in probable DLB. While male DLB patients have a more widespread pattern of cortical atrophy at younger ages, these sex differences tend to disappear with increasing age. Longitudinal studies will help establish these cross-sectional findings and inform on sex and age considerations to the use of MRI in clinical routine, as the field moves towards precision medicine.